Moreover, increased expression of PIM-2 was directly associated with various malignancies, such as non-Hodgkin's lymphoma, CLL and prostate cancer [10]–[13], further supporting the oncogenic function ascribed to PIM-2, and justifying targeting its kinase activity as a beneficial therapeutic approach [21], [35]. Here, PIM2 is linked to B-cell chronic lymphocytic leukemia.